TL;DR: The Centers for Medicare & Medicaid Services modified NCD 6, the National Coverage Determination governing cellular therapy under Medicare, effective January 9, 2026. The policy maintains a blanket non-coverage determination — cellular therapy is not reimbursable under Medicare. Here's what billing teams need to know.
CMS cellular therapy coverage policy under NCD 6 in the CMS Medicare system has not opened up. If anything, this modification reinforces a hard line that has held for decades. No specific CPT or HCPCS codes are listed in the policy document — and that absence is itself a signal. There is nothing to bill. There is no path to reimbursement.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cellular Therapy |
| Policy Code | NCD 6 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Low (for revenue) — High (for denial risk if billed) |
| Specialties Affected | Any specialty that administers or bills for cellular or biological injection therapies not covered by other Medicare policy |
| Key Action | Confirm your charge capture has no active billing pathway for cellular therapy services under Medicare — before January 9, 2026 |
CMS Cellular Therapy Coverage Criteria and Medical Necessity Requirements 2026
NCD 6 is the National Coverage Determination that governs Medicare's position on cellular therapy. The Centers for Medicare & Medicaid Services defines cellular therapy specifically as the injection of humans with foreign proteins — including material derived from the placenta or lungs of unborn lambs.
That clinical description matters. CMS does not treat cellular therapy as unproven or emerging. The agency classifies it as a practice that lacks scientific or statistical evidence of therapeutic efficacy and identifies it as potentially dangerous. That is a harder stance than "investigational."
Under section 1862(a)(1) of the Social Security Act, Medicare only covers services that are reasonable and necessary. CMS has determined that cellular therapy does not meet that standard — full stop. There is no coverage criteria to meet, no documentation that qualifies a patient, and no prior authorization pathway that opens a door here.
The medical necessity bar for Medicare coverage is two-part: the service must be appropriate for the diagnosis, and it must be supported by evidence. CMS has ruled that cellular therapy fails both prongs. Your billing team should treat this like a statutory exclusion, not a documentation challenge.
CMS Cellular Therapy Exclusions and Non-Covered Indications
The coverage policy under NCD 6 carries no list of partially covered indications or conditional exceptions. The entire scope of cellular therapy — as defined by CMS — is excluded.
This is not a situation where certain diagnoses qualify and others don't. There is no ICD-10 code that makes this service billable to Medicare. There is no clinical scenario where documentation tips the scales toward coverage. The policy is categorical.
The real issue here is confusion with other therapies. Cellular therapy as defined in NCD 6 is a narrow, specific practice involving injection of animal-derived biological material. It is not the same as CAR-T therapy, stem cell transplantation, or other cellular-based treatments covered under separate Medicare policies. If your practice bills for those services, this NCD does not govern them. But if anyone on your team is conflating these categories, that's a claim denial waiting to happen.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Injection of foreign proteins (e.g., placental or lamb lung material) into humans | Not Covered | No specific codes listed | Fails medical necessity under section 1862(a)(1); considered potentially dangerous |
| Any cellular therapy indication under NCD 6 scope | Not Covered | No specific codes listed | No prior authorization pathway; no documentation override available |
CMS Cellular Therapy Billing Guidelines and Action Items 2026
This policy modification took effect January 9, 2026. The action items here are about protecting your practice from exposure, not capturing revenue.
| # | Action Item |
|---|---|
| 1 | Audit your charge master before January 9, 2026 for any billing codes mapped to cellular therapy services as defined in NCD 6. If a code exists in your system with a Medicare billing pathway attached to it, remove or suppress that pathway now. |
| 2 | Train your coding team on the clinical definition. NCD 6 defines cellular therapy narrowly — injections of foreign animal proteins. Make sure coders and billers know what this does and does not include. Misclassifying a covered service as cellular therapy (or vice versa) creates risk in both directions. |
| 3 | Do not submit cellular therapy claims to Medicare expecting a denial for tracking purposes. There is no covered indication, no appeals basis built on medical necessity documentation, and no local coverage determination (LCD) that supplements NCD 6 with regional coverage. Filing claims you know will be denied can create false impression of billing intent. |
| 4 | Check your Medicare Administrative Contractor (MAC) for any supplemental guidance. NCD 6 is a national policy, but your MAC may have issued related articles or local coverage determinations for adjacent services. Confirm that none of your current billing activity is tangled up with this NCD. |
| 5 | If you have patients asking about cellular therapy, document the conversation and the coverage denial basis clearly. Patients may have seen marketing from non-Medicare-covered providers. Your documentation protects both the patient and your practice from ABN (Advance Beneficiary Notice) disputes later. |
| 6 | Talk to your compliance officer if your specialty is adjacent to biological injection therapies of any kind. The line between NCD 6 and covered biological or cellular treatments under other Medicare policies is not always obvious from the billing side. Don't make that call alone. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cellular Therapy Under NCD 6
The NCD 6 policy document does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is itself meaningful for cellular therapy billing.
The absence of codes reflects the categorical nature of the non-coverage determination. CMS has not mapped specific billing codes to this policy because there is no approved billing pathway to document. If a payer policy lists codes, it usually means some claims may be evaluated individually. NCD 6 does not work that way.
No Covered CPT or HCPCS Codes
No CPT or HCPCS codes are listed in NCD 6 as covered under any circumstance.
No Covered ICD-10-CM Diagnosis Codes
No ICD-10-CM diagnosis codes are listed as qualifying indications for cellular therapy under NCD 6.
What This Means for Your Charge Capture
If your billing team encounters a claim that seems to fall under the cellular therapy definition in NCD 6, the correct action is not to look for a code that works. The correct action is to stop the claim before it goes out the door.
If you're unsure whether a specific service your practice provides falls within the scope of NCD 6 versus a separate covered Medicare policy — CAR-T therapy under specific LCD coverage, for example — work with your compliance officer and a billing consultant before the effective date to draw a clean line. These categories are different, but the clinical language in your documentation and charge capture can blur that distinction if no one is watching for it.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.